Antimicrobial Therapeutics and Drug Discovery
- 1st Edition - March 17, 2026
- Latest edition
- Editors: Chengyuan Liang, Lei Tian
- Language: English
Antimicrobial Therapeutics and Drug Discovery is a comprehensive resource that provides an overview of antimicrobial drug discovery. It covers a wide spectrum of pathogenic organi… Read more
Description
Description
Antimicrobial Therapeutics and Drug Discovery is a comprehensive resource that provides an overview of antimicrobial drug discovery. It covers a wide spectrum of pathogenic organisms causing human infections, exploring alternative therapeutic strategies beyond traditional small molecule drugs. The contents in the book are structured into four parts, each focusing on a different aspect of antimicrobial drug discovery. From exploring viral and host targets, understanding antibiotic resistance mechanisms, to the potential of nanomedicine and computational approaches, the book offers a comprehensive view of the field. Employing a multidisciplinary approach, chapters discuss the importance of drug discovery for fungi, Mycobacteria, Mycoplasma, and parasites, and offers insights into innovative biomedical approaches and combination therapies. By bridging the gap between experimental research and practical application, Antimicrobial Therapeutics and Drug Discovery is a key reference for pharmacologists and pharmaceutical scientists working in academic and corporate research. Medicinal chemists and microbiologists will also benefit from the multidisciplinary coverage of the book.
Key features
Key features
- Provides a comprehensive overview of antimicrobial drug discovery
- Discusses ethical imperatives in combating antimicrobial resistance
- Offers insights into drug discovery for overlooked pathogens
- Explores alternative therapeutic strategies for combating antibiotic resistance
- Bridges the gap between experimental research and practical application
Readership
Readership
Academic and Corporate research professionals in the fields of pharmacology, medicinal chemistry, and microbiology
Table of contents
Table of contents
Part I: Antiviral Drug Discovery
1. Exploring Viral and Host Targets for Antiviral Drug Discovery
2. COVID-19 Challenges and its Therapeutics
3. From Lab to Clinic: The Evolution of Reverse Transcriptase Inhibitors in HIV Treatment
4. Targeting Hepatitis C Virus Polymerase: Non-Nucleoside Inhibitors (NNIs) and Drug Resistance
5. Challenges, Progress, and Prospects of Drug Discovery to Treat Chronic Hepatitis B (CHB) Infection
6. Discovery and Development of Antiviral Therapies for Influenza Virus Infections
7. Medicinal Chemistry Strategies for the Discovery and Development of Anti-Herpesvirus Drugs
8. Opportunities and Challenges in Targeted Protein Degradation for Antiviral Drug Discovery
Part II: Antibacterial Drug Discovery
9. Molecular Mechanisms of Antibiotic Resistance
10. Overview of the Antibiotics Approved in the Last Two Decades: Retrospect and Prospect
11. Antibiotic Resistance Breakers: Current Approaches and Future Directions
12. Innovative Approaches in Developing Antimicrobial Peptides for Drug-Resistant Bacterial Infections
13. The Potential of Antibody-Antibiotic Conjugates in Combatting Bacterial Diseases
14. Phage Therapy: Current Advancements and Future Prospects in Combating Antimicrobial Resistance
Part III: Drug Discovery for Miscellaneous Pathogens
15. Antifungal Drug Resistance: Current Mechanisms and Future Directions
16. Challenges, Unmet Clinical Needs, and Novel Approaches in the Discovery of Antifungal Drugs
17. Drug Discovery against Mycobacteria: The Success and Challenges
18. Future of Drug Development for the Treatment of Mycoplasma Infections
19. Antimalarial Drug Discovery: From Novel Molecules to Clinical Development
Part IV: Next-Generation Antimicrobial Strategies
20. Computational Approaches in Antimicrobial Drug Discovery
21. Multi-Omics Approaches for Antimicrobial Drug Discovery
22. Nanomedicine as a Next-Generation Antimicrobial Therapy: New Frontiers in Fighting Microbial Infections
23. Drug Repurposing: Innovative Antimicrobial Strategies to Combat Resistance
24. Drug Combinations: A Strategy to Extend the Life of Antimicrobials
25. Ethical Imperatives in Combating Antimicrobial Resistance: A Global Perspective
1. Exploring Viral and Host Targets for Antiviral Drug Discovery
2. COVID-19 Challenges and its Therapeutics
3. From Lab to Clinic: The Evolution of Reverse Transcriptase Inhibitors in HIV Treatment
4. Targeting Hepatitis C Virus Polymerase: Non-Nucleoside Inhibitors (NNIs) and Drug Resistance
5. Challenges, Progress, and Prospects of Drug Discovery to Treat Chronic Hepatitis B (CHB) Infection
6. Discovery and Development of Antiviral Therapies for Influenza Virus Infections
7. Medicinal Chemistry Strategies for the Discovery and Development of Anti-Herpesvirus Drugs
8. Opportunities and Challenges in Targeted Protein Degradation for Antiviral Drug Discovery
Part II: Antibacterial Drug Discovery
9. Molecular Mechanisms of Antibiotic Resistance
10. Overview of the Antibiotics Approved in the Last Two Decades: Retrospect and Prospect
11. Antibiotic Resistance Breakers: Current Approaches and Future Directions
12. Innovative Approaches in Developing Antimicrobial Peptides for Drug-Resistant Bacterial Infections
13. The Potential of Antibody-Antibiotic Conjugates in Combatting Bacterial Diseases
14. Phage Therapy: Current Advancements and Future Prospects in Combating Antimicrobial Resistance
Part III: Drug Discovery for Miscellaneous Pathogens
15. Antifungal Drug Resistance: Current Mechanisms and Future Directions
16. Challenges, Unmet Clinical Needs, and Novel Approaches in the Discovery of Antifungal Drugs
17. Drug Discovery against Mycobacteria: The Success and Challenges
18. Future of Drug Development for the Treatment of Mycoplasma Infections
19. Antimalarial Drug Discovery: From Novel Molecules to Clinical Development
Part IV: Next-Generation Antimicrobial Strategies
20. Computational Approaches in Antimicrobial Drug Discovery
21. Multi-Omics Approaches for Antimicrobial Drug Discovery
22. Nanomedicine as a Next-Generation Antimicrobial Therapy: New Frontiers in Fighting Microbial Infections
23. Drug Repurposing: Innovative Antimicrobial Strategies to Combat Resistance
24. Drug Combinations: A Strategy to Extend the Life of Antimicrobials
25. Ethical Imperatives in Combating Antimicrobial Resistance: A Global Perspective
Product details
Product details
- Edition: 1
- Latest edition
- Published: March 17, 2026
- Language: English
About the editors
About the editors
CL
Chengyuan Liang
Dr. Chengyuan Liang is a Professor at the School of Biological and Pharmaceutical Sciences, Shaanxi University of Science and Technology. He also serves as Director of the Xi’an Key Laboratory for Antiviral and Antimicrobial-Resistant Bacteria Therapeutics Research, the Research Center for the Development of Therapeutic Drugs for Serious Infectious Diseases in Shaanxi Province’s Universities and Colleges, and the Xi’an International Science and Technology Cooperation Base for Anti-Infective Drug Research and Development. His research focuses on medicinal chemistry and translational drug development, including small-molecule antivirals and antibacterials, inhibitors, PROTACs, and antibody-drug conjugates. His work also includes mechanism studies, veterinary drugs, bioequivalence evaluation, natural product modification, and the modernization of classical Chinese medicine through process optimization and quality standards.
Affiliations and expertise
School of Biological and Pharmaceutical Sciences, Shaanxi University of Science and TechnologyLT
Lei Tian
Dr. Lei Tian is a Lecturer at the School of Biological and Pharmaceutical Sciences, Shaanxi University of Science and Technology. She is affiliated with the Engineering Research Center of Major Infectious Disease Therapeutics at Universities of Shaanxi Province and the Xi’an Key Laboratory of Antiviral and Antimicrobial-Resistant Bacteria Therapeutics Research. Her research focuses on medicinal chemistry and anti-infective drug discovery, including targeted protein degradation strategies for pathogenic microorganisms and the development of therapeutics against coronaviruses and multidrug-resistant bacteria. Her work also includes the discovery and optimization of bioactive molecules through chemical synthesis, biological evaluation, pharmacological characterization, mechanism-of-action studies, and preclinical drug development.
Affiliations and expertise
School of Biological and Pharmaceutical Sciences, Shaanxi University of Science and TechnologyView book on ScienceDirect
View book on ScienceDirect
Read Antimicrobial Therapeutics and Drug Discovery on ScienceDirect